![](\"https:\/\/www.thestreet.com\/.image\/NDA6MDAwMDAwMDAzMjI5NjYx\/eli-lilly-ceo-dave-ricks-speaks-at-the-economic-club-of-new-york.jpg?profile=rss\")
<\/p>\n<\/p>\n
For many years, a major barrier to popular weight-loss medications has been straightforward: although millions of Americans may want them, many cannot afford them.<\/p>\n
Eli Lilly (LLY) is beginning to demonstrate what occurs when that barrier is removed.<\/p>\n
More than 500,000 people have joined a Medicare pilot offering eligible older adults and people with disabilities access to obesity drugs for $50 a month, according to Reuters.<\/p>\n
For Lilly, this increased access contributed to yet another huge quarter.<\/p>\n
The pharmaceutical business increased its sales prediction for 2026 to between $91 billion and $92 billion after reporting $24.4 billion in third-quarter revenue, up 39% from the same period last year.<\/p>\n
Lilly’s market worth might increase by over $80 billion after shares surged 7.5% on Thursday and hit a record.<\/p>\n
The fact that Zepbound and Mounjaro are selling well isn’t the only intriguing aspect for investors.<\/p>\n
In fact, Lilly’s realized prices decreased throughout the quarter.<\/p>\n
The business gained a lot more clients to make up for it.<\/p>\n
This might indicate the next stage of the weight-loss medication boom: reduced costs could not be detrimental to Lilly if they significantly expand the market.<\/p>\n
Eli Lilly is trading price for millions of potential patients<\/p>\n
Lilly’s third-quarter results demonstrate the strength of that trade-off.<\/p>\n
Worldwide revenue increased 39% to $24.4 billion.<\/p>\n
Sales volume rose 53%, while realized prices declined 15%, according to Eli Lilly’s earnings release.<\/p>\n
This indicates that even though Lilly made less money per unit on average, it sold a lot more medications.<\/p>\n
In the U.S., revenue increased 34% to $15.1 billion. Volume rose 41%, while realized prices declined 7%.<\/p>\n
Sales of Lilly’s obesity medication Zepbound reached $5.35 billion in the third quarter, a 49% increase over the same period last year.<\/p>\n
More Healthcare\/Health:<\/p>\n
Health insurance is about to cost you a lot more in 2027<\/p>\n
Medicare shoppers face a hidden AI problem this open enrollment<\/p>\n
Pepsi, Nestle could save 150,000 lives a year with one simple change<\/p>\n
Approved for Type 2 diabetes, Mounjaro brought in $10.72 billion, a 65% increase.<\/p>\n
Those are huge figures already.<\/p>\n
However, because insurance coverage and cost have generally limited obesity therapy, the potential market remains considerably larger.<\/p>\n
That may decide if a prescription becomes a real therapy for a typical patient.<\/p>\n
A doctor may suggest a medication for weight reduction, but it won’t help if the patient has to pay hundreds of dollars each month.<\/p>\n
That computation is altered when insurance coverage is increased.<\/p>\n
Reuters reported that Lilly’s Medicare pilot offers eligible older Americans and people with disabilities obesity medication for $50 per month. More than 500,000 customers have already enrolled in the program.<\/p>\n
Therefore, Lilly may be able to reach clients who previously could not afford its products by agreeing to a cheaper price.<\/p>\n
One patient paying less may negatively impact pricing.<\/p>\n
On an income statement, hundreds of thousands of additional patients may seem quite different.<\/p>\n
Lower prices are becoming part of Lilly’s growth story<\/p>\n
The traditional pharmaceutical model often rewards companies for maintaining high prices on successful drugs.<\/p>\n
Weight-loss medications might be evolving differently.<\/p>\n
Because there are so many prospective patients, Lilly could increase overall sales even if it sacrifices some income per prescription.<\/p>\n
Its most recent quarter illustrates this dynamic.<\/p>\n
According to Lilly, the 15% drop in realized price was more than compensated by the 53% rise in global sales volume.<\/p>\n
The disparity was considerably more noticeable outside of the United States.<\/p>\n
Revenue increased 47% to $9.3 billion as volume jumped 76%, despite realized prices falling 29%, according to Lilly.<\/p>\n
Mounjaro’s foreign sales reached $5.7 billion, a 93% increase.<\/p>\n
The addition of Mounjaro to China’s National Reimbursement Drug List, which helps increase access but typically requires drugmakers to accept lower prices, contributed to part of the price decrease.<\/p>\n
The pattern is important because it illustrates the potential evolution of Lilly’s opportunity.<\/p>\n
It is not necessary for the business to charge the maximum amount to every patient.<\/p>\n
To get access, begin therapy, and continue taking its medications, it needs a sufficient number of patients.<\/p>\n
For someone who is having trouble paying for therapy, it is a much more relevant scenario.<\/p>\n
Additionally, it could be a more effective business strategy for Lilly.<\/p>\n
More money may be made from a less expensive medication that serves a much wider population than from a more expensive medication that is only accessible to a small number of patients.<\/p>\n
Eli Lilly just showed why cheaper drugs can be bullish<\/p>\n
Bloomberg \/ Getty Images<\/p>\n
Eli Lilly’s weight-loss boom is getting even bigger<\/p>\n
Wall Street’s response indicates that investors are beginning to think the technique is effective.<\/p>\n
Lilly shares rose 7.5% Thursday to $1,389 after touching a record $1,408.34.<\/p>\n
The rally potentially added about $80 billion to a company already worth roughly $1.2 trillion.<\/p>\n
For a firm the size of Lilly, such a stock rise is impressive.<\/p>\n
Examining management’s expectations makes the explanation more apparent.<\/p>\n
From its initial range of $85 billion to $87 billion, Lilly increased its full-year sales expectation to between $91 billion and $92 billion.<\/p>\n
That is a $5.5 billion increase in projected yearly income over the company’s initial projection at the halfway mark.<\/p>\n
Additionally, Zepbound is not the only component of the company’s obesity business.<\/p>\n
According to Reuters, Lilly has introduced Foundayo, its oral obesity therapy, and is still working on retatrutide, a next-generation injectable medication that, in midstage testing, resulted in an average weight reduction of around 24%.<\/p>\n
This allows Lilly to reach individuals who may not want, be able to pay, or be eligible for the same therapy in a variety of ways.<\/p>\n
Patients who are hesitant to utilize injections may find pills appealing.<\/p>\n
Increased insurance coverage may attract individuals who were previously unable to pay for medical care.<\/p>\n
Having enough medication readily available for everyone who needs it is another issue that has continually hampered the business and may be addressed by increasing production capacity.<\/p>\n
To make it happen, Lilly is making significant investments.<\/p>\n
The business is still growing its manufacturing operations in the United States, including initiatives in Virginia and Texas.<\/p>\n
In the end, such factories are important to patients because the weight-loss boom won’t be fully widespread until pharmaceutical companies can produce enough dosages at costs that consumers or their insurance companies can afford.<\/p>\n
Lilly’s biggest opportunity may be making weight loss less exclusive<\/p>\n
There is still a major risk in Lilly’s strategy. Lower prices only work if additional volume is large enough to compensate. The latest quarter shows that happening. It doesn’t guarantee it will continue forever.<\/p>\n
Additionally, competition is becoming fiercer. While several pharmaceutical firms are developing injectable and oral obesity therapies, Novo Nordisk continues to be a significant competitor.<\/p>\n
Governments and insurers may have more power to drive down pricing when additional medications hit the market.<\/p>\n
That may be excellent news for patients.<\/p>\n
It increases the significance of scale for Lilly.<\/p>\n
The business must continue to draw in new clients more quickly than falling costs reduce earnings.<\/p>\n
So far, that equation is working. Third-quarter volume rose 53%. Revenue rose 39%. Zepbound sales rose 49%. Mounjaro sales rose 65%.<\/p>\n
Additionally, Lilly increased its projected yearly income by billions of dollars while accepting lower actual pricing.<\/p>\n
For this reason, the Medicare pilot’s 500,000 new patients could end up being more significant than Thursday’s record stock price.<\/p>\n
For many years, the weight-loss drug boom was partially a tale of exclusivity and scarcity: although there were exceptional medications, many individuals who desired them were unable to afford them due to their high cost and lack of coverage.<\/p>\n
The most recent data from Lilly suggests a different stage.<\/p>\n
Each prescription may become less profitable if insurance, governments, and pharmaceutical companies are able to make obesity therapy accessible to a substantially wider audience.<\/p>\n
However, the number of prescriptions might be far higher.<\/p>\n
This implies that medications previously considered expensive specialist items may become more widely available to those struggling to pay for treatment.<\/p>\n
It explains why declining prices do not always translate into declining earnings for Lilly investors.<\/p>\n
Making weight-loss medications affordable for millions of Americans might be the largest potential.<\/p>\n
Related: Goldman Sachs resets Eli Lilly 12-month stock price target before earnings<\/p>\n
#Eli #Lilly #stock #surges #cheaper #drugs #unlock #bigger #market<\/p>\n","protected":false},"excerpt":{"rendered":"
For many years, a major barrier to popular weight-loss medications has been straightforward: although millions…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[259],"tags":[2486,2657,758,11171,11172,33,91,304,4083],"_links":{"self":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts\/19487"}],"collection":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19487"}],"version-history":[{"count":0,"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts\/19487\/revisions"}],"wp:attachment":[{"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19487"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19487"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19487"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}